Gastroenterology

Top Medical News
Any polyps spell risk of colorectal cancer
Yesterday
Patients with sporadic ampullary tumours more commonly have colorectal polyps or neoplasia than healthy controls, a recent study has found.
ENT-01 relieves constipation in patients with Parkinson’s disease
Yesterday
Oral ENT-01 safely and significantly improves constipation in patients with Parkinson’s disease (PD), results of a phase IIb study have shown.
Lactobacillus probiotics provide little relief for diarrhoea
Tristan Manalac, Yesterday
A recent meta-analysis has showed little evidence supporting the use of probiotics containing a combination of Lactobacillus acidophilus and L. bulgaricus for the treatment of diarrhoea.
Esophagogastric junction biopsy may be forgone after endoscopic eradication of BE
Yesterday
Random histological sampling from the esophagogastric junction (EGJ) appears to hold low clinical relevance in patients who have undergone successful endoscopic eradication of all visible Barrett’s esophagus (BE), given that the incidence of intestinal metaplasia at the EGJ does not pose a higher risk of disease recurrence, according to a study.
What is the optimal time interval between stent placement and surgery?
Tristan Manalac, 2 days ago
In patients with left-sided malignant colorectal obstruction (LMCO), deferring surgery for >4 weeks after placement of self-expanding metallic stent (SEMS) appears to yield better short-term clinical outcomes, according to a recent study.
FRESCO-2: Fruquintinib improves OS in heavily pretreated mCRC
Elaine Soliven, 4 days ago
Fruquintinib, a highly selective and potent oral tyrosine kinase inhibitor of VEGFR*-1, -2, and -3, significantly improves overall survival (OS) in heavily pretreated patients with metastatic colorectal cancer (mCRC), according to the FRESCO-2** trial presented at ESMO 2022.
Intermittent fasting may not be healthy after all
Elvira Manzano, 4 days ago
Currently in vogue, intermittent fasting (IF) – which switches between periods of eating and fasting – may not be as beneficial as many have thought.
Special Reports
FRESCO-2: Fruquintinib improves OS in heavily pretreated mCRC
Elaine Soliven, 30 Nov 2022
Fruquintinib, a highly selective and potent oral tyrosine kinase inhibitor of VEGFR*-1, -2, and -3, significantly improves overall survival (OS) in heavily pretreated patients with metastatic colorectal cancer (mCRC), according to the FRESCO-2** trial presented at ESMO 2022.
Product Highlight - Ravida
13 Sep 2022
Ravidasvir 200 mg tab
Product Highlight - Salofalk
12 Mar 2021
SALOFALK – Mesalazine 1.5 g PR granules
Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma
Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).  

Role of genomics in colorectal cancers
Dr Joslyn Ngu, 04 Dec 2017

Advancements in genomics has paved the way for better classifications of colorectal cancers (CRC) and the use of precision therapy.

Conference Reports
Could a single screening colonoscopy prevent CRC?
Roshini Claire Anthony, 16 Nov 2022

Results of the NordICC* trial from Europe, presented at the United European Gastroenterology Week (UEG 2022), have hinted at the benefit of a single screening colonoscopy in preventing colorectal cancer (CRC).

Is vonoprazan an alternative to pantoprazole in preventing post-EVL ulcers, bleeding?
Roshini Claire Anthony, 08 Nov 2022

Vonoprazan may be as effective as pantoprazole in reducing the risk of ulcers or bleeding following endoscopic variceal ligation (EVL) in patients with portal hypertension, according to a small study from Egypt presented at the United European Gastroenterology Week (UEG 2022).

Tucatinib-trastuzumab combo induces durable tumour response in HER2+ mCRC
Elvira Manzano, 19 Sep 2022
Dual HER-2 inhibition with tucatinib and trastuzumab induces clinically meaningful and durable responses in patients with previously treated metastatic HER2-positive colorectal cancer (mCRC) in the phase II MOUNTAINEER trial, boosting hopes for this chemotherapy-free combination.
Any upside to frontline mFOLFOXIRI-panitumumab in mCRC?
Roshini Claire Anthony, 14 Sep 2022

In patients with unresectable RAS and BRAF wildtype metastatic colorectal cancer (mCRC), a modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN*) treatment strategy in the first-line setting did not improve objective response rate (ORR) compared with FOLFOX plus panitumumab (mFOLFOX6/PAN**), results of the phase III TRIPLETE study showed.

STRIDE regimen benefit in unresectable HCC consistent across baseline liver function
Roshini Claire Anthony, 11 Sep 2022

The overall survival (OS) benefit observed with the STRIDE regimen compared with sorafenib in patients with unresectable hepatocellular carcinoma (HCC) is consistent regardless of baseline liver function, according to exploratory analysis of data from the phase III HIMALAYA trial presented at ESMO GI 2022.

Second-line NIVO + IPI combo sustains response, OS benefit in aHCC
Elaine Soliven, 30 Aug 2022
The combination of nivolumab 1 mg/kg (NIVO1) and ipilimumab 3 mg/kg (IPI3) every 3 weeks followed by NIVO 240 mg every 2 weeks in the second-line setting continues to confer durable response and overall survival (OS) benefit in patients with advanced hepatocellular carcinoma (aHCC), according to 5-year data from the CheckMate 040* trial presented at ESMO GI 2022.
Durvalumab + gemcitabine-cisplatin confers benefit in biliary tract cancer
Roshini Claire Anthony, 27 Aug 2022

The benefit of adding durvalumab to gemcitabine plus cisplatin chemotherapy in patients with advanced biliary tract cancer (BTC) was consistent regardless of primary tumour location, according to a subgroup analysis of the phase III TOPAZ-1 study presented at ESMO GI 2022.